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Drug eluting stentsIn recent years an angiographic score was introduced in clinical practice to stratiﬁed different levels of risk after
percutaneous coronary interventions (PCI) with drug eluting stents. The SYNTAX score (SS) classiﬁed patients in
three different risk levels and was included in revascularization guidelines that patients allocated with low SS
could be equally treated with either PCI or CABG, whereas those with intermediate or high SS were better off
with CABG. However, using original SS each coronary lesion with a diameter stenosis ≥50% in vessels ≥1.5 mm
was scored.
In ERACI IV registry we used a revascularization strategy during PCI where operators were advised to only treat
lesions ≥ than 70% in a ≥ 2.0mmreference vessel; therefore, no intermediate lesions should be treated, and severe
stenosis in vessels b 2.0 mmwas discouraged as well.
If we recalculated SS using the above-mentioned operators' advices all intermediate lesions were not scored, and
severe stenosis in vessels b 2.0 mm were excluded for the analysis, including bifurcations, trifurcations and
chronic total occlusions; after this new scoring, the original SS dropped signiﬁcantly which is in accordance
with the goal of complete functional revascularization strategy of the ERACI IV study and the low one year
adverse events of such study. In conclusion, if we performed an SS scoring, only severe stenosis in vessels with
a reference diameter ≥2.0 mm would allow a more rational assessment of coronary anatomy, and the use of a
more conservative PCI strategy.driguez)
This is an©2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).In recent years an angiographic score was introduced in clinical
practice to stratiﬁed different levels of risk after percutaneous coronary
interventions (PCI) with drug eluting stents (DES).
Investigators from the SYNTAX trial [1,2]—whichwas a randomized
comparison between PCI with implantation of a 1st generation DES
(Taxus, Express, Boston Scientiﬁc, Marlborough, MA, USA) versus coro-
nary artery bypass graft (CABG) in patients with three-vessel coronary
artery disease (CAD) or unprotected left main — designed and created
an anatomic angiographic score to identiﬁed different risk levels in the
outcome from those patients included and treated in the SYNTAX trial.
This score was called Syntax Score (SS), and almost immediately
after SYNTAX trial released the results, SS started being used as a risk
score worldwide.
The SYNTAX lesion score was calculated by grading 11 types of
lesions, answering sequential interactive questions taking into account:
number of disease segments, tortuosity, heavy calciﬁcation, presence of
thrombus, lesion length, dominance, bifurcation, trifurcation, aorto.
open access article under thostial lesions, diffuse disease, and total occlusion [2], and each coronary
lesion with a diameter stenosis ≥50% in vessels ≥1.5 mmwas scored.
The SS classiﬁed patients in three different risk levels: low SS, when
they scored 22 or less; intermediate, when they were between 23 and
32; and high when the score was 33 or higher.
Despite the fact that SINTAX was not designed and powered to
stratiﬁed outcomeswith PCI and CABG according to SS, it was concluded
that patients allocated with low SS could be equally treated with either
PCI or CABG,whereas thosewith intermediate or high SSwere better off
with CABG. These ﬁndings were rapidly included in revascularization
guidelines [3].
However, this score had some limitations. First, it was only an
anatomic score, and functional assessment of lesions during PCI was
correlated with better patient outcome [4]. Also, SS did not have any
predictive value if patients were treated with CABG; in fact it had no
relationship with other risk scores such as Euroscore. Also, since the
SS was not validated in other large randomized trials such as FREEDOM
[5], authors from the original paper recently published new SS, adding
new clinical and anatomic variables [6].
The SYNTAX trial [1] was designed to achieve complete anatomic
revascularization either with PCI or CABG, therefore all lesions withe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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treated accordingly. In the trial, stent length was 84.6 mm. For the past
three years, we conducted a prospective, multicenter, controlledFig. 1. Example from an ERACI IV patient. SYNTAX score vs. Modiﬁed ERACI IV SYNTAX
score. PT ID:01-082SYNTAX score=37 (red and white arrows)Modiﬁed ERACI IV SYNTAX
score=31 (only red arrows, white arrowswere not scored). A. Right coronary artery with
proximal severe stenosis scored; mid intermediate lesion and severe lesion in small (b2.0
mm) posterior descending artery were not scored. B. Both intermediate lesions in obtuse
marginal not scored. C. Both severe stenosis in proximal and mid portion of left anterior
descendent artery were scored.registry called ERACI IV, using a 2nd generationDES (Firebird 2,Microport
Inc, Shangai, China) in patients with two or three-vessel CAD and unpro-
tected left main [7,8]. One year follow-up was recently reported [8].
In contrast with SYNTAX, in ERACI IV the stent length immediately
after PCIwas only 41.4mm in spite of the 27.7 SS shown in the study [8].
The differences in stent length observed in both studies (86.4mmvs.
41.4mm in SYNTAX and ERACI IV respectively, p b 0.001)were not cor-
relatedwith the differences in SS (p=0.04), suggesting large variability
in PCI strategy. In fact, in ERACI IV, the goal was to achieve complete
functional revascularization [9], and operators were advised to only
treat lesions ≥ than 70% in a ≥ 2.0 mm reference vessel, provisional
stent in all bifurcations was recommended, no intermediate lesions
were treated and, ﬁnally, severe stenosis (≥70%) in vessels b 2.0 mm
was discouraged as well [7,8].
Taking into account the original high SS found in ERACI IV, total stent
length of this study appears to be quite low, and, for this reason,
we recalculated SS now following the above-mentioned operator advice
for the study [7,8], thus, with these new measures, all intermediate
lesions were not scored, and severe stenosis in vessels b 2.0 mm were
excluded for the analysis, including bifurcations, trifurcations and
chronic total occlusions. In-stent restenosis, allowed to enter in ERACI
IV, was scored as heavy calciﬁed lesion; all other angiographic variables
were measured according to the original SS. As an example, if a patient
had intermediate stenosis (50% to 69%) in a heavy calciﬁed, tortuous
and diffusemajor epicardial vessel, these angiographic characteristics—
which were scored in the original SS — had no value now, within
the new assessment, due the presence of an intermediate stenosis.
Therefore, all the above-mentioned variables, together with intermediate
stenosis, were not scored (Fig. 1).
After this new scoring, the original SS dropped from 27.7 to 22.02
which is in accordance with the number of stents deployed and stent
length seen in ERACI IV [8].
In ERACI IV, aswe can see in Fig. 2, still using the original SS, 33.8% of
patients were low, 32.4% intermediate and 33.8% high. After the new
scoring, low SS rose to 54.8%, intermediate dropped to 27.9% and only
17.2% of ERACI's patients scored a high SS.
In addition, excluding all intermediate lesions and severe stenosis in vessels
b2mm, the number of diseased vessels also changed, with the new scoring
13.4% had 1 vessel CAD, 59.8% 2 vessel CAD and 26.8% 3 vessel CAD.
Although a signiﬁcant safety/efﬁcacy improvement was observed
with latest generation DES, presence of neo atherosclerosis remained
[10], a fact that favors a more conservative strategy during PCI.
Park recently published theﬁrst randomized studyutilizing everolimus
DES vs. CABG formultiple vessel disease [11].Major adverse cardiac events
(MACCE) at 4.6 yearswere higherwith DES, 15.3% vs. 10.6% for CABG, p=
0.04, and this was mainly driven by the occurrence of spontaneous myo-
cardial infarction (p = 0.02) and need for target vessel (p = 0.03) or
new lesion revascularization in the DES group (p = 0.01). In this trial,
total stent length was 85.3 mm in spite a quite low SS of 24.2, suggesting
that— similar to SYNTAX— an aggressive PCI strategy was used.
We do recognize some limitations for this sort of score: ﬁrst we do
not use functional assessment of the lesions, and it is well known that
several intermediate lesions will have similar fractional ﬂow reserve
compromise to a single severe stenosis [12] therefore, the accuracy of
visual assessment of a coronary lesion outside the context of an acute
coronary syndrome is ﬂawed in most of cases. Functional assessment
using FFR should become gold-standard in all patients with stable CAD
undergoing PCI with stent implantation as was recently suggested
[13], although we are aware that FFR is often not covered in many
healthcare systemsworldwide. In addition, most of the patients includ-
ing in ERACI IV had had functional thallium stress test previous to the
PCI procedure [9,14]. Finally, our remarkable low one year rate of
MACCE in ERACI IV [8] is probably due to a combination of factors, in-
cluding the use of second generation DES together with our PCI strategy
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Fig. 2. Classical SYNTAX score and Modiﬁed by ERACI IV Syntax score comparison from ERACI IV trial population.
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will result in a low 5-year MACCE rate.
In conclusion, if we performed an SS scoring, only severe stenosis in
vessels with a reference diameter ≥2.0mmwould allow amore rational
assessment of coronary anatomy, and the use of amore conservative PCI
strategy that could be associated with a low events rate.References
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